Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celularity Inc. stock logo
CELU
Celularity
$2.35
-1.3%
$1.76
$1.00
$5.22
$56.28M0.61333,558 shs16,532 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$9.72
-2.6%
$9.70
$8.06
$18.75
$129.94M1.7446,385 shs39,235 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$2.04
+15.3%
$2.03
$1.12
$4.20
$151.66M1.01234,957 shs168,057 shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$0.41
-0.1%
$0.45
$0.39
$2.80
$121.09M-0.251.03 million shs298,991 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celularity Inc. stock logo
CELU
Celularity
-1.26%+11.90%+50.26%+92.62%-30.27%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-2.61%-0.10%-3.19%-15.77%-26.31%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
+15.25%+3.55%-7.27%-12.82%+15.91%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-0.15%0.00%-7.03%-42.48%-85.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celularity Inc. stock logo
CELU
Celularity
0.1567 of 5 stars
0.01.00.00.01.71.70.0
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.0266 of 5 stars
3.50.00.00.03.33.30.0
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
1.4062 of 5 stars
3.30.00.00.02.10.00.6
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
2.2424 of 5 stars
2.80.00.00.02.15.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celularity Inc. stock logo
CELU
Celularity
0.00
N/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00301.23% Upside
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.50
Moderate Buy$6.50218.63% Upside
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
1.50
Reduce$1.00143.90% Upside

Current Analyst Ratings Breakdown

Latest CELU, LYEL, GLSI, and IKT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
4/16/2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
3/28/2025
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/13/2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celularity Inc. stock logo
CELU
Celularity
$54.22M1.04$9.79 per share0.24$2.11 per share1.11
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.52 per shareN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$260K583.30N/AN/A$1.78 per share1.15
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$65K1,862.90N/AN/A$2.60 per share0.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celularity Inc. stock logo
CELU
Celularity
-$196.29M-$2.65N/AN/A-72.72%-119.53%-25.40%7/28/2025 (Estimated)
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$234.63M-$1.25N/AN/AN/A-323,792.09%-34.64%-30.02%8/6/2025 (Estimated)

Latest CELU, LYEL, GLSI, and IKT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/13/2025Q1 2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$0.19-$0.18+$0.01-$0.18N/A$0.01 million
5/8/2025Q4 2024
Celularity Inc. stock logo
CELU
Celularity
-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 million
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
3/12/2025Q4 2024
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$0.20-$0.72-$0.52-$0.72N/A$0.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celularity Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celularity Inc. stock logo
CELU
Celularity
N/A
0.19
0.14
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
6.91
6.91
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
0.85
0.85
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/A
13.43
13.43

Institutional Ownership

CompanyInstitutional Ownership
Celularity Inc. stock logo
CELU
Celularity
19.02%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
66.05%

Insider Ownership

CompanyInsider Ownership
Celularity Inc. stock logo
CELU
Celularity
22.10%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.67%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
7.30%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
25.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celularity Inc. stock logo
CELU
Celularity
22023.95 million18.55 millionOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.35 millionNot Optionable
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
674.34 million66.18 millionNot Optionable
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
270295.34 million218.83 millionOptionable

Recent News About These Companies

Lyell Immunopharma announces FDA granted RMAT designation to LYL314

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celularity stock logo

Celularity NASDAQ:CELU

$2.35 -0.03 (-1.26%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$2.33 -0.02 (-0.85%)
As of 05/28/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$9.72 -0.26 (-2.61%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$9.34 -0.38 (-3.90%)
As of 05/28/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NYSE:IKT

$2.04 +0.27 (+15.25%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$2.04 +0.00 (+0.25%)
As of 05/28/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Lyell Immunopharma stock logo

Lyell Immunopharma NASDAQ:LYEL

$0.41 0.00 (-0.15%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.42 +0.01 (+1.46%)
As of 05/28/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.